Recursion Pharmaceuticals (RXRX) Current Assets (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Current Assets came in at $709.6 million in Q1 2026, up 21.47% YoY from $584.1 million in Q1 2025, and down 12.71% on a QoQ basis from $812.8 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Current Assets (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Current Assets data on file, last reported at $709.6 million in Q1 2026.
- Quarterly Current Assets rose 21.47% year-over-year to $709.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $709.6 million (up 21.47% YoY) and the FY2025 annual result came in at $812.8 million, up 13.8% from the prior year.
- Current Assets retreated to $709.6 million in Q1 2026, from $812.8 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $812.8 million in Q4 2025 to a low of $343.6 million in Q1 2024.
- A 5-year average of $555.9 million and a median of $546.0 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets jumped 179.26% — and 2024, when it sank 30.18%.
- Tracing RXRX's Current Assets over 5 years: stood at $569.8 million in 2022, then dropped by 23.11% to $438.1 million in 2023, then jumped by 63.02% to $714.3 million in 2024, then advanced by 13.8% to $812.8 million in 2025, then dropped by 12.71% to $709.6 million in 2026.
- The last three Current Assets figures came in at $709.6 million (Q1 2026), $812.8 million (Q4 2025), and $714.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 603.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 603.46 Mn |
| Mar 31, 2026 | 709.56 Mn |
| Dec 31, 2025 | 812.85 Mn |
| Sep 30, 2025 | 714.11 Mn |
| Jun 30, 2025 | 587.16 Mn |
| Mar 31, 2025 | 584.15 Mn |
| Dec 31, 2024 | 714.27 Mn |
| Sep 30, 2024 | 474.17 Mn |
| Jun 30, 2024 | 522.38 Mn |
| Mar 31, 2024 | 343.62 Mn |
| Dec 31, 2023 | 438.14 Mn |
| Sep 30, 2023 | 410.52 Mn |
| Jun 30, 2023 | 431.02 Mn |
| Mar 31, 2023 | 492.13 Mn |
| Dec 31, 2022 | 569.81 Mn |
| Sep 30, 2022 | 481.62 Mn |
| Jun 30, 2022 | 546.00 Mn |
| Mar 31, 2022 | 619.46 Mn |
| Dec 31, 2021 | 534.72 Mn |
| Sep 30, 2021 | 600.87 Mn |